7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT®) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Botulism is a rare, sometimes fatal paralytic illness caused by botulinum neurotoxins. BAT® (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine)) is an equine-derived heptavalent botulinum antitoxin indicated for the treatment of symptomatic botulism in adult and pediatric patients. This review assesses the cumulative safety profile for BAT product from 2006 to 2020, using data received from clinical studies, an expanded-access program, a post-licensure registry, spontaneous and literature reports. The adverse event (AE) incidence rate for BAT product was calculated conservatively using only BAT product exposures for individuals with a record (512) and was alternatively estimated using all BAT product exposure data, including post-licensure deployment information (1128). The most frequently reported BAT product-related AEs occurring in greater than 1% of the 512-1128 BAT product-exposed individuals were hypersensitivity, pyrexia, tachycardia, bradycardia, anaphylaxis, and blood pressure increase reported in 2.3-5.1%, 1.8-3.9%, 1.0-2.2%, 0.89-2.0%, 0.62-1.4%, and 0.62-1.4%, respectively. For patients properly managed in an intensive care setting, the advantages of BAT product appear to outweigh potential risks in patients due to morbidity and mortality of botulism. AEs of special interest, including bradycardia, hemodynamic instability, hypersensitivity, serum sickness, and febrile reactions in the registry, were specifically solicited.

          Related collections

          Author and article information

          Journal
          Toxins (Basel)
          Toxins
          MDPI AG
          2072-6651
          2072-6651
          December 27 2021
          : 14
          : 1
          Affiliations
          [1 ] Pharmacovigilance Department, Emergent BioSolutions Canada Incorporated (Inc.), Winnipeg, MB R3T 5Y3, Canada.
          [2 ] Biostatistics Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
          [3 ] Clinical Research Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
          Article
          toxins14010019
          10.3390/toxins14010019
          8778610
          35050996
          420e8813-0f01-49fc-b41e-e1cd793b78e1
          History

          equine-derived,BAT product,Botulism Antitoxin Heptavalent,botulism,safety review

          Comments

          Comment on this article